Compare Gilead Sciences, Inc. (GILD) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Yum China Holdings Inc — how do they compare? Gilead Sciences, Inc. trades at $133.18 (market cap $163.51B), while Yum China Holdings Inc trades at $44.56 (market cap $14.84B). The key difference: Gilead Sciences, Inc. is far larger — about 11× Yum China Holdings Inc's market cap, and Yum China Holdings Inc pays the higher dividend (2.69%). Which is the better fit depends on your goals.
| GILD | YUMC | |
|---|---|---|
Market Cap | $163.51B | $14.84B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $57.95 |
52-Week Low | $108.22 | $40.18 |
Enterprise Value | $178.05B | $15.73B |
Dividend Yield | 2.49% | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Yum China Holdings (YUMC) trades at $43.30, down 1.37% today, with a bullish technical signal supported by moving averages. The company shows consistent revenue growth from $9.6B in 2022 to $11.8B in 2025, with net income reaching $929M. Recent strategic moves include acquiring full ownership of Pizza Hut in mainland China and announcing a $1.5B capital return plan for 2026. Valuation metrics appear reasonable with P/E of 16.54 and P/S of 1.3.
YUMC presents a compelling investment case with strong analyst support (74% buy ratings), consistent earnings beats, and strategic expansion in China's QSR market. Key risks include Chinese consumer spending volatility and intense competition. The upcoming Q2 2026 earnings report on July 30 will be crucial for validating growth trajectory amid ongoing market challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
